Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.

Title : Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice

Source : PubMed
ID : 10751862
Authors : Dowling AJ, Czaykowski PM, Krahn MD, Moore MJ, Tannock IF
Year : 2001
Disease Category : Cancer
Focused Population : Not Specified
Priori/Posteriori : Posteriori
Single-study Generalibility? : Single
Score/Non-Score : Non-score
Tutorial/Method : NHANES_T2D
Compared general demographic and patient characteristics : Yes
Compared disease-specific clinical characteristics : No
Compared adverse events : No
Compared outcomes/treatment effect (including survival) : Yes
Trial participants vs. general population (from EHR, survey, a cohort, etc) : Yes
Real-world data sources : hospital data
Target Population Data Type Levels : Hospital
Descriptive Statistics : Yes
Test characteristics between two groups? : Yes
Chi squared test : Yes
Fisher exact test : Yes
Treatment effect : Yes
Cox proportional hazard models : Yes